JP2021522306A5 - - Google Patents

Info

Publication number
JP2021522306A5
JP2021522306A5 JP2020561817A JP2020561817A JP2021522306A5 JP 2021522306 A5 JP2021522306 A5 JP 2021522306A5 JP 2020561817 A JP2020561817 A JP 2020561817A JP 2020561817 A JP2020561817 A JP 2020561817A JP 2021522306 A5 JP2021522306 A5 JP 2021522306A5
Authority
JP
Japan
Prior art keywords
degrees
buprenorphine
diffraction pattern
ray powder
powder diffraction
Prior art date
Application number
JP2020561817A
Other languages
English (en)
Japanese (ja)
Other versions
JP7421804B2 (ja
JP2021522306A (ja
JPWO2019214726A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/086449 external-priority patent/WO2019214726A1/en
Publication of JP2021522306A publication Critical patent/JP2021522306A/ja
Publication of JPWO2019214726A5 publication Critical patent/JPWO2019214726A5/ja
Publication of JP2021522306A5 publication Critical patent/JP2021522306A5/ja
Priority to JP2023079918A priority Critical patent/JP2023106478A/ja
Application granted granted Critical
Publication of JP7421804B2 publication Critical patent/JP7421804B2/ja
Priority to JP2025074417A priority patent/JP2025121948A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561817A 2018-05-11 2019-05-10 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 Active JP7421804B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023079918A JP2023106478A (ja) 2018-05-11 2023-05-15 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
JP2025074417A JP2025121948A (ja) 2018-05-11 2025-04-28 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670714P 2018-05-11 2018-05-11
US62/670,714 2018-05-11
PCT/CN2019/086449 WO2019214726A1 (en) 2018-05-11 2019-05-10 Long-acting injectable formulations and crystalline forms of buprenorphine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023079918A Division JP2023106478A (ja) 2018-05-11 2023-05-15 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形

Publications (4)

Publication Number Publication Date
JP2021522306A JP2021522306A (ja) 2021-08-30
JPWO2019214726A5 JPWO2019214726A5 (https=) 2022-05-18
JP2021522306A5 true JP2021522306A5 (https=) 2022-05-18
JP7421804B2 JP7421804B2 (ja) 2024-01-25

Family

ID=68466685

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020561817A Active JP7421804B2 (ja) 2018-05-11 2019-05-10 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
JP2023079918A Pending JP2023106478A (ja) 2018-05-11 2023-05-15 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
JP2025074417A Pending JP2025121948A (ja) 2018-05-11 2025-04-28 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023079918A Pending JP2023106478A (ja) 2018-05-11 2023-05-15 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
JP2025074417A Pending JP2025121948A (ja) 2018-05-11 2025-04-28 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形

Country Status (14)

Country Link
US (2) US11524965B2 (https=)
EP (1) EP3790881B1 (https=)
JP (3) JP7421804B2 (https=)
KR (2) KR102839314B1 (https=)
CN (1) CN111954672B (https=)
AR (1) AR117426A1 (https=)
AU (1) AU2019266795B2 (https=)
BR (1) BR112020016576A2 (https=)
CA (1) CA3089256C (https=)
MX (1) MX2020008471A (https=)
NZ (1) NZ766474A (https=)
TW (1) TWI838372B (https=)
WO (1) WO2019214726A1 (https=)
ZA (1) ZA202004582B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
GB202019594D0 (en) * 2020-12-11 2021-01-27 Univ London Queen Mary Sustained release formulations of crystalline drugs
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物
IL317873A (en) * 2022-06-24 2025-02-01 Alar Pharmaceuticals Inc Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途
EP4719414A2 (en) * 2023-06-02 2026-04-08 Board of Regents of the University of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO121631B1 (ro) 1999-08-27 2008-01-30 Southern Research Institute Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool
DE60329515D1 (de) 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
GB0606124D0 (en) 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
US9272044B2 (en) * 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
FR2975912B1 (fr) * 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
EP2970188A4 (en) 2013-03-15 2016-10-19 Vm Therapeutics Llc NOVEL CRYSTALLINE FORMS
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN107660207B (zh) * 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
TWI743193B (zh) * 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina

Similar Documents

Publication Publication Date Title
JP2021522306A5 (https=)
AU2020410549B2 (en) Long-acting injectable formulations of ketamine pamoate salts
JP2015521617A5 (https=)
JP7421804B2 (ja) ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
JP2019524670A5 (https=)
KR20180119610A (ko) 즉시 사용가능한 케토로락 제제
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2019516739A5 (https=)
HRP20170450T1 (hr) Prstenaste n,n′-diariltiouree i n,n′-diariluree kao antagonisti androgenskog receptora, sredstvo protiv raka, postupak njihovog dobivanja i njihove upotrebe
JP2018538273A5 (https=)
JP2016537338A5 (https=)
HRP20130092T4 (hr) Karbamoil-cikloheksani za lijeäśenje akutne manije
RU2017131354A (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
HRP20151138T1 (hr) Dihidroetorfini i njihovo pripremanje
JPWO2019214726A5 (https=)
RU2008152751A (ru) Соли тримебутина и n-десметилтримебутина
JP6347784B2 (ja) 神経筋遮断薬の安定化水性組成物
HRP20040560A2 (en) Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
EP3251695B1 (en) Aqueous preparation for external use
KR880001593A (ko) 4-(아로일아미노)피페리딘부탄아미드 유도체
RU2024115713A (ru) Инъекционные препараты длительного действия и кристаллические формы производных бупренорфина
JP2019516722A5 (https=)
RU2020131600A (ru) Инъекционные препараты длительного действия и кристаллические формы производных бупренорфина
JP2018095567A5 (https=)
RU2010147833A (ru) Пролекарства налмефена